Heart Medicine Multaq (Dronedarone) Can Cause Severe Liver Damage
Previously, the heart medicine dronedarone received FDA approval "to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter." Dronedarone is marketed to the public as Multaq.
On January 14, 2011, the FDA issued a severe liver injury warning on Dronedarone/Multaq. FDA notified healthcare professionals and patients about cases of rare, but severe liver injury. Two patients have required liver transplants. Information about the potential risk of liver injury from dronedarone is being added to the WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS sections of the dronedarone labels.
If you have taken or are currently taking the heart medicine Multaq to control atrial fibrillation or flutter, contact the law firm of Berger & Lagnese for a free consultation.